pancreatic ductal adenocarcinoma (Cancer)
Information
- Disease name
- pancreatic ductal adenocarcinoma
- Disease ID
- DOID:3498
- Description
- "A pancreatic adenocarcinoma that derives_from pancreatic duct cells." [url:http\://cancergenome.nih.gov/cancersselected/PancreaticDuctalAdenocarcinoma, url:http\://en.wikipedia.org/wiki/Pancreatic_cancer]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04692740 | Active, not recruiting | Phase 2 | Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) | December 18, 2020 | December 2023 |
| NCT05031494 | Active, not recruiting | Phase 2 | A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers | December 8, 2021 | January 2024 |
| NCT01013649 | Active, not recruiting | Phase 3 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | April 5, 2010 | February 13, 2025 |
| NCT03915444 | Active, not recruiting | Phase 2 | Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma | July 15, 2019 | July 31, 2023 |
| NCT04662112 | Active, not recruiting | Phase 1/Phase 2 | Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma | June 15, 2021 | December 30, 2024 |
| NCT04913337 | Active, not recruiting | Phase 1/Phase 2 | Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | June 9, 2021 | July 2025 |
| NCT05462717 | Active, not recruiting | Phase 1 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | September 19, 2022 | December 2025 |
| NCT04483726 | Active, not recruiting | N/A | Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA) | July 9, 2020 | July 9, 2025 |
| NCT04469556 | Active, not recruiting | Phase 2 | Pancreatic Adenocarcinoma Signature Stratification for Treatment | October 14, 2020 | September 2026 |
| NCT04862260 | Active, not recruiting | Early Phase 1 | Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma | October 4, 2021 | December 31, 2026 |
| NCT03267316 | Active, not recruiting | Phase 1/Phase 2 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | September 19, 2017 | December 31, 2023 |
| NCT02498613 | Active, not recruiting | Phase 2 | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | August 31, 2016 | April 10, 2025 |
| NCT05432193 | Active, not recruiting | Phase 1 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | July 13, 2022 | December 2026 |
| NCT04853017 | Active, not recruiting | Phase 1 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors | October 4, 2021 | March 2026 |
| NCT04634539 | Active, not recruiting | Phase 1 | Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer | May 13, 2021 | July 6, 2025 |
| NCT04827953 | Active, not recruiting | Phase 1/Phase 2 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer | September 1, 2021 | September 30, 2024 |
| NCT06302881 | Active, not recruiting | Differentiating Tumor-stroma Ratio in Pancreatic Ductal Adenocarcinoma | January 2013 | March 2024 | |
| NCT00878163 | Active, not recruiting | Phase 1 | GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery | March 31, 2009 | March 7, 2025 |
| NCT04257448 | Active, not recruiting | Phase 1/Phase 2 | Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer | May 25, 2020 | March 2024 |
| NCT04115527 | Active, not recruiting | N/A | Should a Standard Lymphadenectomy Include the No. 16 Lymph Nodes for Patients With Pancreatic Head Adenocarcinoma. | June 1, 2018 | December 31, 2023 |
| NCT00669734 | Active, not recruiting | Phase 1 | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | February 1, 2010 | April 23, 2025 |
| NCT03486327 | Active, not recruiting | Phase 2 | Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions | July 19, 2018 | March 31, 2024 |
| NCT03496662 | Active, not recruiting | Phase 1/Phase 2 | BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | August 31, 2018 | October 14, 2024 |
| NCT03608631 | Active, not recruiting | Phase 1 | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | January 27, 2021 | April 30, 2025 |
| NCT04752696 | Active, not recruiting | Phase 2 | Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma | February 3, 2021 | March 11, 2024 |
| NCT05042128 | Active, not recruiting | Phase 2 | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1/LSTA1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | April 13, 2022 | October 1, 2024 |
| NCT04310111 | Completed | N/A | EUS-RFA for Unresectable Pancreatic Cancer | March 1, 2020 | August 25, 2021 |
| NCT03410030 | Completed | Phase 1/Phase 2 | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) | December 15, 2017 | January 10, 2022 |
| NCT03415854 | Completed | Phase 2 | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) | January 31, 2018 | December 11, 2023 |
| NCT01188785 | Completed | Phase 1 | Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas | January 2011 | December 2013 |
| NCT03517176 | Completed | Phase 1 | CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer | July 31, 2018 | June 19, 2020 |
| NCT01280058 | Completed | Phase 2 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | December 2010 | January 20, 2016 |
| NCT03592888 | Completed | Phase 1 | DC Vaccine in Pancreatic Cancer | November 20, 2018 | February 12, 2024 |
| NCT01580397 | Completed | Phase 2 | Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer | May 16, 2012 | July 2, 2013 |
| NCT03770117 | Completed | Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease | October 4, 2018 | July 1, 2019 | |
| NCT03794128 | Completed | A Study of Personalized Neoantigen Cancer Vaccines | July 25, 2018 | May 26, 2020 | |
| NCT01547260 | Completed | Phase 1/Phase 2 | Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer | October 2009 | November 2014 |
| NCT04954378 | Completed | Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer | January 1, 2010 | December 30, 2020 | |
| NCT04802993 | Completed | Survival Among Patients With Pancreatic Cancer Depending on Surgical Resection Rate | January 1, 2010 | October 2, 2020 | |
| NCT04740164 | Completed | N/A | A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP | February 14, 2021 | May 4, 2023 |
| NCT02042378 | Completed | Phase 2 | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | April 2014 | May 2016 |
| NCT02259114 | Completed | Phase 1 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | October 23, 2014 | March 3, 2017 |
| NCT02426281 | Completed | Phase 2 | Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma | June 4, 2015 | September 30, 2022 |
| NCT02440958 | Completed | Phase 2 | Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial | August 28, 2015 | March 2, 2017 |
| NCT02527434 | Completed | Phase 2 | Study of Tremelimumab in Patients With Advanced Solid Tumors | November 2, 2015 | March 28, 2023 |
| NCT04596865 | Completed | Recurrence After Whipple's (RAW) Study | October 12, 2020 | June 30, 2023 | |
| NCT02677038 | Completed | Phase 2 | Olaparib in Treating Patients With Stage IV Pancreatic Cancer | November 11, 2016 | July 18, 2022 |
| NCT04580485 | Completed | Phase 1 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | February 3, 2021 | February 22, 2024 |
| NCT02767700 | Completed | NGS and TME for Evidence-based Treatment of Pancreatic Cancer | April 2016 | August 31, 2018 | |
| NCT02787187 | Completed | N/A | Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended? | July 1, 2016 | October 2021 |
| NCT02790944 | Completed | Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer | May 4, 2016 | August 15, 2020 | |
| NCT05476978 | Completed | Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions | July 1, 2022 | January 24, 2024 | |
| NCT06344299 | Completed | Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma | January 1, 2023 | September 30, 2023 | |
| NCT02959164 | Completed | Phase 1 | Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma | December 5, 2016 | October 16, 2020 |
| NCT02981342 | Completed | Phase 2 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | January 12, 2017 | November 9, 2018 |
| NCT00588367 | Completed | CT Pancreas Perfusion | April 2006 | February 2009 | |
| NCT03257150 | Completed | N/A | A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer | September 22, 2017 | July 14, 2022 |
| NCT03291938 | Completed | Phase 1 | IACS-010759 in Advanced Cancers | November 13, 2017 | November 23, 2020 |
| NCT06199752 | Completed | Phase 4 | Synergistic Immunomodulatory Effect of Synbiotics Pre and Postoperative Resection of Pancreatic Ductal Adenocarcinoma | December 12, 2021 | September 10, 2023 |
| NCT03973736 | Completed | Impact of Multidisciplinary and Radiologic Review on Outcome of Pancreatic Cancer Patients: an Observational Study | June 15, 2018 | January 15, 2019 | |
| NCT05048810 | Completed | N/A | Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma | February 7, 2020 | March 1, 2023 |
| NCT01658943 | Completed | Phase 2 | Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy | August 2012 | June 2015 |
| NCT03693378 | Completed | A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups | January 19, 2016 | November 12, 2021 | |
| NCT04793633 | Enrolling by invitation | Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic Cancer | January 31, 2024 | December 30, 2030 | |
| NCT06275737 | Not yet recruiting | N/A | POP-UP: a Single-arm, Two-cohort Study: Trimodal Prehab for Upper GI and Pancreatic Cancer | March 2024 | March 2027 |
| NCT06287749 | Not yet recruiting | French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC) | March 1, 2024 | October 31, 2028 | |
| NCT06276803 | Not yet recruiting | The LINFU® U.S. Registry for the in the General Population Without Risk Factors | June 15, 2024 | June 15, 2034 | |
| NCT06214533 | Not yet recruiting | N/A | Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery | March 1, 2024 | December 31, 2025 |
| NCT06151691 | Not yet recruiting | Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach | December 1, 2023 | November 30, 2025 | |
| NCT06147037 | Not yet recruiting | Phase 1 | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | June 28, 2024 | December 30, 2027 |
| NCT06345599 | Not yet recruiting | Phase 1/Phase 2 | PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study) | May 1, 2024 | January 10, 2027 |
| NCT05314998 | Not yet recruiting | Phase 3 | Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature | June 15, 2024 | September 1, 2031 |
| NCT05611359 | Not yet recruiting | N/A | Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer | January 2023 | December 2026 |
| NCT05632328 | Not yet recruiting | Phase 2 | AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer | April 2024 | May 1, 2027 |
| NCT03806309 | Recruiting | Phase 2 | Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | July 31, 2019 | December 30, 2024 |
| NCT03767582 | Recruiting | Phase 1/Phase 2 | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | December 12, 2019 | December 31, 2024 |
| NCT06115499 | Recruiting | Phase 2/Phase 3 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | December 6, 2023 | December 9, 2029 |
| NCT03727880 | Recruiting | Phase 2 | Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | June 4, 2019 | December 2024 |
| NCT06128551 | Recruiting | Phase 1 | Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors | November 14, 2023 | November 30, 2026 |
| NCT06131840 | Recruiting | Phase 1 | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | November 20, 2023 | March 31, 2030 |
| NCT06445062 | Recruiting | Phase 1/Phase 2 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | May 24, 2024 | July 15, 2027 |
| NCT06388967 | Recruiting | Pancreatic Cancer Detection Consortium | March 15, 2023 | November 21, 2025 | |
| NCT06122896 | Recruiting | Early Phase 1 | Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals | November 21, 2023 | October 31, 2041 |
| NCT03865875 | Recruiting | N/A | Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program | August 13, 2019 | August 2024 |
| NCT06122480 | Recruiting | N/A | Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma | May 21, 2024 | April 1, 2028 |
| NCT06105021 | Recruiting | Phase 1/Phase 2 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | March 6, 2024 | December 2029 |
| NCT04146298 | Recruiting | Phase 1/Phase 2 | Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer | October 21, 2021 | March 2025 |
| NCT04150042 | Recruiting | Phase 1 | SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells | January 13, 2021 | December 2025 |
| NCT06084481 | Recruiting | Phase 1 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | November 9, 2023 | July 1, 2026 |
| NCT06079346 | Recruiting | Phase 2/Phase 3 | A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer | May 1, 2024 | June 1, 2027 |
| NCT04211948 | Recruiting | N/A | Clinical Study Between Robotic and Open Surgery in Patients With Pancreatic Cancer | March 1, 2019 | December 2024 |
| NCT06151223 | Recruiting | A Prospective Registry for Patients at High-Risk for Pancreatic Cancer | July 13, 2021 | July 2031 | |
| NCT06077487 | Recruiting | Phase 4 | Ketamine-assisted Therapy for Patients With Pancreatic Ductal Adenocarcinoma | May 17, 2024 | December 31, 2024 |
| NCT04291651 | Recruiting | UCSF PANC Cyst Registry | October 8, 2019 | January 1, 2030 | |
| NCT06060405 | Recruiting | Phase 2 | Durvalumab and Oleclumab in Resectable PDAC | November 29, 2023 | October 30, 2026 |
| NCT06168812 | Recruiting | Phase 2 | A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer | December 5, 2023 | December 5, 2025 |
| NCT05584852 | Recruiting | Prognostic Value of Myosteatosis and Creatinine-to-cystatin C Ratio in Patients With Pancreatic Ductal Adenocarcinoma | November 1, 2022 | May 1, 2023 | |
| NCT04406831 | Recruiting | The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer | April 2015 | April 2027 | |
| NCT04449406 | Recruiting | Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers | January 1, 2020 | January 2024 | |
| NCT06218914 | Recruiting | Phase 1 | A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation | February 5, 2024 | January 2, 2040 |
| NCT04477343 | Recruiting | Phase 1 | A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | November 23, 2020 | December 31, 2025 |
| NCT04480268 | Recruiting | Phase 4 | PAXG Out in the Country | July 8, 2020 | January 1, 2026 |
| NCT05634720 | Recruiting | Phase 4 | Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer | January 2, 2024 | June 30, 2028 |
| NCT06287463 | Recruiting | Phase 1/Phase 2 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | May 14, 2024 | August 2027 |
| NCT02757859 | Recruiting | N/A | High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery | April 27, 2016 | January 2025 |
| NCT06305247 | Recruiting | Phase 1/Phase 2 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | April 3, 2024 | March 20, 2028 |
| NCT04605237 | Recruiting | Pancreatic Cancer Recurrence in the Netherlands | January 1, 2014 | July 1, 2023 | |
| NCT06048484 | Recruiting | Phase 2 | Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma | June 2024 | April 2027 |
| NCT06320717 | Recruiting | AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma | January 2, 2024 | July 2, 2026 | |
| NCT06330441 | Recruiting | N/A | Pancreatic Cancer Screening in a Population at High Risk | January 7, 2022 | January 6, 2028 |
| NCT01983410 | Recruiting | A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma | November 4, 2013 | November 2025 | |
| NCT04712721 | Recruiting | Early Phase 1 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. | October 14, 2021 | June 26, 2024 |
| NCT04726956 | Recruiting | A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC | February 1, 2021 | February 1, 2023 | |
| NCT05983133 | Recruiting | Phase 1 | A Study of SGN-EGFRd2 in Advanced Solid Tumors | November 14, 2023 | September 30, 2028 |
| NCT05977322 | Recruiting | Phase 1 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | October 6, 2023 | January 26, 2027 |
| NCT05964621 | Recruiting | Venous Thromboembolism in Primary Pancreatic Tumour Resection | September 1, 2023 | October 1, 2024 | |
| NCT06041009 | Recruiting | Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations | December 20, 2023 | September 30, 2025 | |
| NCT06015724 | Recruiting | Phase 2 | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer | January 31, 2024 | January 2026 |
| NCT05955157 | Recruiting | Phase 2/Phase 3 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | January 3, 2023 | June 2025 |
| NCT05955092 | Recruiting | Exploring the Application of 3D Bioprinting for Personalized Treatment in Pancreatic Ductal Adenocarcinoma | December 1, 2022 | September 30, 2024 | |
| NCT04851119 | Recruiting | Phase 1/Phase 2 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | November 8, 2021 | June 30, 2028 |
| NCT06015659 | Recruiting | Phase 2 | ZN-c3 + Gemcitabine in Pancreatic Cancer | November 16, 2023 | June 1, 2027 |
| NCT05915351 | Recruiting | Phase 2 | Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) | June 30, 2023 | June 1, 2026 |
| NCT05867121 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | October 2, 2023 | December 30, 2025 |
| NCT05851924 | Recruiting | Phase 2 | A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) | May 12, 2023 | May 2026 |
| NCT04927780 | Recruiting | Phase 3 | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer | September 7, 2021 | July 2029 |
| NCT05846516 | Recruiting | Phase 1 | A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02) | March 13, 2023 | March 2027 |
| NCT04969731 | Recruiting | Phase 3 | Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | September 7, 2021 | June 2027 |
| NCT04970056 | Recruiting | Pancreatic Cancer Early Detection Consortium | September 18, 2020 | December 31, 2030 | |
| NCT04975217 | Recruiting | Early Phase 1 | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | December 14, 2021 | December 31, 2026 |
| NCT04976634 | Recruiting | Phase 2 | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | August 18, 2021 | March 22, 2027 |
| NCT04999761 | Recruiting | Phase 1 | AB122 Platform Study | June 1, 2021 | May 2026 |
| NCT05799274 | Recruiting | Phase 1 | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer | November 9, 2023 | September 2024 |
| NCT05737615 | Recruiting | Phase 1 | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9 | February 10, 2023 | February 10, 2025 |
| NCT05048524 | Recruiting | Phase 2 | Peri-operative SLOG for Localized Pancreatic Cancer | September 3, 2021 | August 24, 2025 |
| NCT05727319 | Recruiting | Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC) | November 17, 2022 | May 2024 | |
| NCT05132504 | Recruiting | Phase 2 | Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer | August 31, 2022 | December 31, 2024 |
| NCT05141643 | Recruiting | Early Phase 1 | Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer | November 18, 2021 | November 18, 2025 |
| NCT05209074 | Recruiting | Phase 1 | Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma | September 8, 2022 | October 15, 2024 |
| NCT05254171 | Recruiting | Phase 2/Phase 3 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | August 8, 2022 | January 1, 2027 |
| NCT06005493 | Recruiting | Phase 1/Phase 2 | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | July 11, 2023 | December 11, 2026 |
| NCT05726864 | Recruiting | Phase 1/Phase 2 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors | April 14, 2023 | November 2026 |
| NCT05296421 | Recruiting | N/A | Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer | March 14, 2022 | July 1, 2026 |
| NCT05303090 | Recruiting | Phase 1 | Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer | March 31, 2022 | March 28, 2025 |
| NCT05630989 | Recruiting | A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy | February 7, 2023 | February 2025 | |
| NCT05336266 | Recruiting | Early Phase 1 | A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma | July 1, 2022 | December 5, 2025 |
| NCT05346536 | Recruiting | N/A | Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC) | June 16, 2022 | September 1, 2024 |
| NCT05355298 | Recruiting | Phase 1/Phase 2 | ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | May 31, 2022 | May 1, 2025 |
| NCT05365893 | Recruiting | Early Phase 1 | PHL Treatment in Pancreatic Cancer | October 20, 2021 | December 31, 2024 |
| NCT05431270 | Recruiting | Phase 1 | Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor (the MORNINGSTAR Study) | August 11, 2022 | August 2025 |
| NCT05708599 | Recruiting | N/A | A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer | February 7, 2023 | February 7, 2028 |
| NCT05440942 | Recruiting | Phase 1 | Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | January 19, 2023 | September 2027 |
| NCT05692596 | Recruiting | The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | October 6, 2022 | August 2025 | |
| NCT05641896 | Recruiting | Phase 2 | Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers | April 28, 2023 | March 31, 2025 |
| NCT05482893 | Recruiting | Phase 1/Phase 2 | PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) | March 15, 2023 | April 2026 |
| NCT05498597 | Recruiting | Phase 1 | AMT-151 in Patients With Selected Advanced Solid Tumours | January 25, 2023 | October 30, 2024 |
| NCT05546853 | Recruiting | Phase 1 | Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma | March 28, 2023 | November 28, 2025 |
| NCT05563272 | Recruiting | Phase 2 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors | June 6, 2023 | December 29, 2025 |
| NCT03851237 | Recruiting | Phase 1 | CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy | January 2, 2019 | June 30, 2025 |
| NCT04111172 | Suspended | Phase 2 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | November 10, 2020 | December 31, 2024 |
| NCT03444948 | Suspended | N/A | A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma | February 14, 2019 | May 1, 2028 |
| NCT04779151 | Suspended | Phase 2 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab | April 7, 2021 | December 2027 |
| NCT04042480 | Terminated | Phase 1 | A Study of SGN-CD228A in Advanced Solid Tumors | September 3, 2019 | March 9, 2023 |
| NCT01096732 | Terminated | Phase 2 | Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) | February 2011 | August 2012 |
| NCT01431794 | Terminated | Phase 1/Phase 2 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | December 27, 2011 | November 5, 2018 |
| NCT01962909 | Terminated | Early Phase 1 | Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer | November 2013 | January 2016 |
| NCT02050997 | Terminated | Plasma Biomarkers P-DAC, V1 | May 26, 2014 | December 2021 | |
| NCT03012282 | Terminated | N/A | CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer | June 22, 2017 | June 1, 2022 |
| NCT03481920 | Terminated | Early Phase 1 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer | January 10, 2018 | June 10, 2019 |
| NCT03525392 | Terminated | Phase 1 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | May 3, 2018 | April 28, 2021 |
| NCT03852836 | Terminated | N/A | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images | February 26, 2019 | September 15, 2021 |
| NCT03890198 | Terminated | Early Phase 1 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma | April 22, 2019 | March 6, 2020 |
| NCT03979066 | Terminated | Phase 2 | Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma | November 1, 2019 | November 3, 2019 |
| NCT04025216 | Terminated | Phase 1 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | October 10, 2019 | December 2, 2022 |
| NCT00307723 | Terminated | Phase 1/Phase 2 | Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer | May 2006 | July 2009 |
| NCT04046887 | Terminated | Phase 1 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) | September 11, 2019 | October 4, 2023 |
| NCT04400903 | Terminated | Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer | September 21, 2020 | September 30, 2022 | |
| NCT04565327 | Terminated | Phase 2 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | August 14, 2020 | November 1, 2022 |
| NCT05289830 | Terminated | Phase 2 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | August 5, 2022 | August 27, 2023 |
| NCT05257993 | Unknown status | Phase 1 | Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer | March 2022 | August 2023 |
| NCT03634332 | Unknown status | Phase 2 | Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | May 1, 2019 | January 2021 |
| NCT03435770 | Unknown status | N/A | Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms | March 1, 2018 | September 1, 2019 |
| NCT03317886 | Unknown status | Phase 3 | Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer | December 1, 2017 | November 30, 2021 |
| NCT03316326 | Unknown status | Phase 2 | S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer | November 1, 2017 | December 31, 2021 |
| NCT03221400 | Unknown status | Phase 1/Phase 2 | PEN-866 in Patients With Advanced Solid Malignancies | August 29, 2017 | June 2023 |
| NCT03138213 | Unknown status | N/A | Comparing Total Laparoscopic Versus Open Pancreaticoduodenectomy | May 1, 2018 | May 1, 2022 |
| NCT03076372 | Unknown status | Phase 1 | A Study Evaluating MM-310 in Patients With Solid Tumors | February 22, 2017 | December 2018 |
| NCT02929797 | Unknown status | Early Phase 1 | Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer | August 2016 | August 2019 |
| NCT02926183 | Unknown status | Phase 2 | Study of NAC of GA Therapy for Patients With BRPC | October 2016 | September 2021 |
| NCT02607826 | Unknown status | N/A | Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors | November 2016 | March 2019 |
| NCT01942629 | Unknown status | Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas | October 2013 | December 2015 | |
| NCT01879878 | Unknown status | N/A | Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial] | December 2013 | December 2015 |
| NCT01676259 | Unknown status | Phase 2 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer | March 7, 2018 | August 2023 |
| NCT04797676 | Unknown status | Effects of Different Methods of PDAC Specimen Acquisition on Primary Cell Culture and Application | January 15, 2021 | February 28, 2022 | |
| NCT04794140 | Unknown status | N/A | A Clinical Study to Evaluated Which Number of Passes of EUS-FNB is Better for Culturing Primary Cells of PDAC | January 15, 2021 | January 31, 2022 |
| NCT04189393 | Unknown status | Microbiome Analysis in esoPhageal, PancreatIc and Colorectal CaNcer Patients Undergoing Gastrointestinal Surgery | January 1, 2020 | November 1, 2021 | |
| NCT04164992 | Unknown status | N/A | Endoscopic Ultrasound Radiofrequency Ablation (EUS-RFA) of Not-resectable Pancreatic Cancer | November 15, 2019 | November 15, 2021 |
| NCT03951324 | Unknown status | Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study | May 10, 2019 | December 31, 2019 | |
| NCT03820661 | Unknown status | N/A | High Resolution Ultrasound in Pancreatic Ductal Adenocarcinoma | February 1, 2019 | December 2022 |
| NCT03687853 | Unknown status | N/A | Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery | January 1, 2017 | December 31, 2019 |
| NCT04852367 | Withdrawn | Phase 1 | PanDox: Targeted Doxorubicin in Pancreatic Tumours | June 16, 2021 | March 30, 2023 |
| NCT02570529 | Withdrawn | Phase 4 | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy | October 2015 | February 2018 |
| NCT02414100 | Withdrawn | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy | December 12, 2013 | December 15, 2016 | |
| NCT04632199 | Withdrawn | Phase 1 | Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer. | March 12, 2021 | December 10, 2021 |
| NCT04306861 | Withdrawn | Novel MRI Techniques for Pancreatic Cancer | March 9, 2020 | August 30, 2022 | |
| NCT04262388 | Withdrawn | Phase 2 | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation | January 2021 | January 2023 |
| NCT01911416 | Withdrawn | N/A | A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer | January 2014 | October 2014 |
| NCT03432676 | Withdrawn | Phase 2 | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | July 31, 2019 | April 30, 2021 |
| NCT04134468 | Withdrawn | Phase 2 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | January 2020 | November 11, 2022 |
| NCT03374852 | Withdrawn | Phase 2 | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer | August 2018 | October 2020 |
| NCT03908333 | Withdrawn | Phase 1/Phase 2 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | May 1, 2019 | May 1, 2023 |
| NCT02575508 | Withdrawn | Phase 1/Phase 2 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | ||
| NCT03697239 | Withdrawn | Phase 1/Phase 2 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | June 2019 | December 2022 |
- Disase is a (Disease Ontology)
- DOID:4074
- Cross Reference ID (Disease Ontology)
- NCI:C9120
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:792907004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1335302
- Exact Synonym (Disease Ontology)
- ductal adenocarcinoma of the pancreas